Elsevier

Neuroscience

Volume 38, Issue 3, 1990, Pages 571-577
Neuroscience

Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease

https://doi.org/10.1016/0306-4522(90)90051-5Get rights and content

Abstract

There is little information about major constituents of the brain in Alzheimer's disease. In the case of amino acids most of the previous data are contradictory. These have been interpreted in an anatomic and neurotransmitter as well as a metabolic context.

To help clarify this, the contents of 14 amino acids and ethanolamine were determined in samples of neocortex from diagnostic craniotomies of 15 demented patients (10 with Alzheimer's disease) and other neurosurgical procedures (57 patients, 18 with intractable depression). A comprehensive survey of the effects of possible complicating factors on the concentrations of amino acids showed that artefacts were few; this was in contrast to a post mortem series of brains (16 with Alzheimer's disease and 16 controls; six regions assayed). We have used the ante mortem data to provide the basis for an accurate comparison of amino acid values between Alzheimer and control samples. In Alzheimer's disease, the mean contents of many amino acids were slightly higher (sum of the increases of those significantly affected was 15 nmol/mg protein) whereas glutamate content alone was significantly reduced (by 16 nmol/mg protein). This was not a feature of depression or a group of patients with other dementias. Glutamate content of Alzheimer samples was related to pyramidal neuron density in cortical layer III.

These alterations were detected relatively early during the course of Alzheimer's disease and are considered to be due to loss of corticocortical glutamatergic association pathways.

Reference (38)

  • BowenD.M.

    Alzheimer's disease

  • BowenD.M. et al.

    Group report. Cell injury: molecular biology and genetic basis

  • CaputoC.B. et al.

    Authors' response to commentaries

    Neurobiol. Aging

    (1989)
  • ChawlukJ.B. et al.

    Positron emission tomography in aging and dementias: effect of cerebral atrophy

    J. Nucl. Med.

    (1987)
  • CooperA.J.L. et al.

    Biochemistry and physiology of brain ammonia

    Physiol. Rev.

    (1987)
  • CrinoP.B. et al.

    Cellular localization of serotonin 1A, IB and uptake sites in the cingulate cortex of the rat

    J. Pharmac. exp. Ther.

    (1990)
  • CutlerN.R. et al.

    Clinical history, brain metabolism and neuropsychological function in Alzheimer's disease

    Ann. Neurol.

    (1985)
  • EllisonD.W. et al.

    A post mortemstudy of amino acid neurotransmitters in Alzheimer's disease

    Ann. Neurol.

    (1986)
  • EsiriM.M. et al.

    A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer's disease

    J. Neurol. Neurosurg. Psychiat.

    (1989)
  • Cited by (97)

    • Electrophysiological differences in cortical excitability in different forms of dementia: A transcranial magnetic stimulation and laboratory biomarkers study

      2020, Neurophysiologie Clinique
      Citation Excerpt :

      In AD, the lower threshold has been linked to overactivation of glutamatergic transmission [46]. It could also be due to selective degeneration of glutamate neurons, resulting in low intracellular glutamate levels that disrupt ion homeostasis and neural energy metabolism [18,33,37] via impairment of (Na+/K+) pump [54]. This reduces the neural membrane potential allowing easier depolarization with reduced threshold for excitation [48].

    • TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models

      2019, Behavioural Brain Research
      Citation Excerpt :

      Changes in the glutamatergic signaling are seen in aging. For example, patients with dementia showed reduced glutamate levels in the CSF [51] and in post-mortem brain [52]. Preclinical studies also suggest that N-methyl-D-aspartate (NMDA) receptor hypofunction is associated with cognitive impairment in aging.

    • Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support

      2017, Neurochemistry International
      Citation Excerpt :

      In the PD field this has led most studies to instead pursue transplantation of cells into the striatum, the target of dopaminergic innervation, rather than the substantia nigra where the disease-affected neurons normally reside. In the case of other neurodegenerative disease that exhibit more widespread pathology and loss of varying neuronal subtypes in multiple brain regions, such as AD, this kind of neuronal replacement paradigm becomes even more challenging (Davies and Maloney, 1976; Davies et al., 1980; Hardy et al., 1987; Hyman et al., 1987; Lowe et al., 1990). How then can NSCs be a reasonable therapy for these more complex neurodegenerative disorders?

    • Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder

      2016, Biochimica et Biophysica Acta - Molecular Basis of Disease
      Citation Excerpt :

      These reactions could alter the glutamate/glutamine balance, which could help explain the elevated glutamate levels seen in CG in this study. We note that other reports of changes in glutamate levels in the AD-brain are contradictory, possibly due to general differences in the measurements performed in ante-mortem and post-mortem tissue [38,39]. An alternative route of glutamate metabolism is via transamination, which involves two linked transamination reactions.

    View all citing articles on Scopus

    Present address: Institute of Molecular and Cell Biology, National University of Singapore, 10 Kent Ridge Crescent, 0511 Singapore.

    View full text